Innovative Medicine Made Accessible to Those in Need Our Story Latest News Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Juniper Biologics Acquires Cell-Mediated Gene Therapy TG-C LD For Treatment of Knee Osteoarthritis Juniper Biologics In-Licenses Helsinn’s Oncology Portfolio For Aloxi®, Onicit®, Paloxi®, Akynzeo® and Anamorelin (INN) Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive